Scroll down to search for clinics conducting this clinical trial.

Study summary

<b>Myelofibrosis - Multiple Locations in the US</b>

If you have been diagnosed with anemia from myeloproliferative neoplasm–associated (MPN-associated) myelofibrosis (MF), you may be eligible to take part in a clinical research study.

Study Purpose:
The INDEPENDENCE Trial is seeking to determine if people with MPN-associated MF who need red blood cell (RBC) transfusions will stop needing transfusions or require less frequent RBC transfusions by taking luspatercept (ACE-536). This study is also evaluating the safety of luspatercept.

All individuals who qualify and enroll will receive either luspatercept or a placebo, as well as study-related exams and study-related laboratory tests, at no cost. The total length of participation is approximately five years.

Eligibility Criteria:
Eligible participants must:

  • Be 18 years of age or older
  • Have a confirmed diagnosis of primary myelofibrosis (PMF), post-essential thrombocythemia MF (post-ET MF), or post-polycythemia vera MF (post-PV MF)
  • Require RBC transfusions given for the treatment of anemia
  • Be on a continuous and stable dose of JAK2 inhibitor therapy

Other protocol-defined inclusion and exclusion criteria apply.

A special website has been created to provide more information about the INDEPENDENCE Trial.
CLICK HERE for more information.

Study is available at

This study is being conducted NATIONWIDE! To find clinics conducting this study near you please use search feature below.

Study Locations